Fuso Pharmaceutical Industries,Ltd. Logo

Fuso Pharmaceutical Industries,Ltd.

Manufactures essential pharmaceuticals like dialysis drugs, infusions, and injections for healthcare.

4538 | T

Overview

Corporate Details

ISIN(s):
JP3823600006
LEI:
Country:
Japan
Address:
大阪市中央区道修町一丁目7番10号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Fuso Pharmaceutical Industries, Ltd. is a manufacturer and seller of pharmaceuticals and medical equipment. Established in 1950, the company specializes in essential medical products, with a core portfolio centered on dialysis-related drugs, infusions, injections, and transfusion fluids. Fuso is actively involved in the research and development of new medicines, maintaining a pipeline of drugs in various clinical trial stages. The company's operations are guided by its mission of "Supporting Life, Nurturing Life," providing critical healthcare solutions to medical institutions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 04:14
Interim Report
確認書
Japanese 9.3 KB
2025-11-12 04:08
Interim Report
半期報告書-第103期(2025/04/01-2026/03/31)
Japanese 194.0 KB
2025-06-26 04:32
Post-Annual General Meeting Information
臨時報告書
Japanese 27.4 KB
2025-06-24 08:02
Governance Information
内部統制報告書-第102期(2024/04/01-2025/03/31)
Japanese 25.2 KB
2025-06-24 08:01
Registration Form
確認書
Japanese 9.4 KB
2025-06-24 08:00
Registration Form
有価証券報告書-第102期(2024/04/01-2025/03/31)
Japanese 1.0 MB
2025-06-03 10:03
Capital/Financing Update
臨時報告書
Japanese 22.6 KB
2025-05-28 09:44
Legal Proceedings Report
臨時報告書
Japanese 23.6 KB
2024-11-12 07:02
Interim Report
確認書
Japanese 9.3 KB
2024-11-12 07:01
Interim Report
半期報告書-第102期(2024/04/01-2025/03/31)
Japanese 189.2 KB
2024-06-26 03:18
Post-Annual General Meeting Information
臨時報告書
Japanese 24.7 KB
2024-06-25 09:19
Governance Information
内部統制報告書-第101期(2023/04/01-2024/03/31)
Japanese 24.1 KB
2024-06-25 09:17
Registration Form
確認書
Japanese 9.4 KB
2024-06-25 09:04
Registration Form
有価証券報告書-第101期(2023/04/01-2024/03/31)
Japanese 1019.3 KB
2024-05-13 10:14
Regulatory News Service
臨時報告書
Japanese 23.1 KB

Automate Your Workflow. Get a real-time feed of all Fuso Pharmaceutical Industries,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Fuso Pharmaceutical Industries,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Fuso Pharmaceutical Industries,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden
ELIC
ELI LILLY & Co Logo
Pharma leader developing medicines for diabetes, obesity, oncology, and neuroscience.
United States of America
LLY
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden
ELN
ELUTIA INC. Logo
Develops drug-eluting biologics to reduce complications from medical implants.
United States of America
ELUT
Emergent BioSolutions Inc. Logo
Develops and manufactures medical countermeasures for public health and national security threats.
United States of America
EBS
ENANTA PHARMACEUTICALS INC Logo
Developing novel small molecule drugs for virology (HCV, RSV) and immunological diseases.
United States of America
ENTA
enGene Holdings Inc. Logo
Developing non-viral, locally administered gene therapies for rare genetic conditions.
United States of America
ENGN
Enliven Therapeutics, Inc. Logo
A clinical-stage biopharma developing kinase inhibitors for precision oncology cancer treatment.
United States of America
ELVN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy that reprograms macrophages to treat immune hyper-responses like sepsis.
United States of America
ENLV
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel
ENLV

Talk to a Data Expert

Have a question? We'll get back to you promptly.